Clinical trial
Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer…
NCT00310011 · Wake Forest University Health Sciences, Other · Completed
Key facts
| NCT number | NCT00310011 |
|---|---|
| Title | Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium |
| Official title | A Phase II Trial of Gemzar (Gemcitabine), Taxol (Paclitaxel), and Platinol (Cisplatin) (GTP) in Treatment of Advanced Transitional Cell Carcinoma of the Urothelium |
| Lead sponsor | Wake Forest University Health Sciences, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter |
| Intervention type | Drug, Procedure |
| Interventions | cisplatin, gemcitabine hydrochloride, paclitaxel, conventional surgery |
| Enrollment | 71 |
| Start date | Jun 1, 1998 |
| Primary completion | Oct 1, 2005 |
| Completion | Aug 1, 2009 |
| First posted | Apr 3, 2006 |
| Last update posted | Aug 10, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: